Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 clinical trial assessing LM008

Next Previous
X
Search
Trial Profile

Phase 3 clinical trial assessing LM008

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegapamodutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Oct 2024 New trial record
    • 30 Sep 2024 According to LeaderMed Group media release, LeaderMed Group (LeaderMed) and Combiphar announce the formation of a joint venture (JV) to conduct the Phase 3 clinical trial of LM-008; Indonesian Ministry of Health, under Minister Budi Gunadi Sadikin, has given guidance on accelerated approval for LM-008, with this Phase 3 clinical trial expected to commence in late 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top